Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Hyponatraemia tied to worse outcome, acute chest syndrome in sickle cell disease patients

20 Sep 2020

Hyponatraemia at admission for an acute painful episode appears to be a robust and independent predictor of worse outcome and acute chest syndrome in patients with sickle cell disease, suggests a recent study.

The investigators carried out this retrospective study between 2010 and 2015 in a French referral centre for sickle cell disease. They sought to examine the value of low plasma sodium concentration at admission in predicting a complication in adult patients with sickle cell disease hospitalized for an initially uncomplicated acute painful episode.

The primary outcome was a composite criterion including acute chest syndrome, intensive care unit (ICU) transfer, red blood cell transfusion, or inpatient death. Analyses were also adjusted for age, sex, haemoglobin genotype and concentration, lactate dehydrogenase concentration, and white blood cell count.

Four hundred six patients with a total of 1,218 hospital stays were included. No inpatient death occurred during the study period.

Hyponatraemia (plasma sodium ≤135 mmol/L) at admission correlated with the primary outcome (adjusted odds ratio [OR], 195, 95 percent confidence interval [CI], 1.3–2.91; p=0.001), acute chest syndrome (OR, 1.95, 95 percent CI, 1.2–3.17; p=0.008), and red blood cell transfusion (OR, 2.71, 95 percent CI, 1.58–4.65; p<0.001), but not significantly with ICU transfer (OR, 1.83, 95 percent CI, 0.94–3.79; p=0.074).

In addition, patients with hyponatraemia at admission had longer adjusted mean length of stay by 1.1 days (95 percent CI, 0.5–1.6; p<0.001).

These findings could help in identifying patients who might benefit from closer monitoring, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.